MRI methods are widely used to follow the pathological evolution of multiple sclerosis in life
and its modification by treatment. To date, measures of the number and volume of …

Brain atrophy has emerged as a clinically relevant component of disease progression in
multiple sclerosis. Progressive loss of brain tissue bulk can be detected in vivo in a sensitive …

Objective To determine gray matter (GM) atrophy rates in multiple sclerosis (MS) patients at
all stages of disease, and to identify predictors and clinical correlates of GM atrophy …

Objective To determine the relation of gray matter (GM) and white matter (WM) brain
volumes, and WM lesion load, with clinical outcomes 20 years after first presentation with …

The secondary progressive phase of multiple sclerosis (MS), which is characterised by a
steady accrual of fixed disability after an initial relapsing remitting course, is not clearly …

Brain atrophy measured by MRI is a potentially useful tool for monitoring disease
progression in multiple sclerosis. The location, extent and mechanisms of brain atrophy in …

BACKGROUND AND PURPOSE: MR-based volumetric measures of cerebral structures are
increasingly used for diagnostic purposes and to measure progression of atrophy. Variations …

Multiple sclerosis (MS), the most frequent demyelinating disease, is characterized by a
variable disease course. The majority of patients starts with relapsing remitting (RR) …

Brain atrophy as determined by quantitative MRI can be used to characterize disease
progression in multiple sclerosis. Many studies have addressed white matter (WM) …

OBJECTIVE (a) To establish whether the cognitive decline of the early phase of relapsing-
remitting multiple sclerosis depends on the progression of the burden of disease, or on the …